Edgewise Therapeutics director granted 319 shares
Fox Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Fox Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
Edgewise Therapeutics director Jonathan C. Fox received a grant of 319 shares of Common Stock. The shares were awarded at a price of $0.00 per share as a compensation-related grant, not an open-market purchase. Following this award, Fox directly holds 24,833 shares of Edgewise Therapeutics common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 319 | $0.00 | $0.00 |
Key Figures
Key Terms
Common Stock financial
Grant, award, or other acquisition financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Edgewise Therapeutics (EWTX) report for Jonathan C. Fox?
Was the Edgewise Therapeutics (EWTX) insider transaction a market buy or a compensation grant?
What transaction code was used in the Edgewise Therapeutics (EWTX) Form 4 for Jonathan C. Fox?
Does the Edgewise Therapeutics (EWTX) Form 4 show any stock sales by Jonathan C. Fox?
AI-generated analysis. How Rhea-AI works. Not financial advice.